These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 18281485)

  • 1. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
    Jeon BH; Jang C; Han J; Kataru RP; Piao L; Jung K; Cha HJ; Schwendener RA; Jang KY; Kim KS; Alitalo K; Koh GY
    Cancer Res; 2008 Feb; 68(4):1100-9. PubMed ID: 18281485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
    Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
    Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
    Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
    Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
    Björndahl MA; Cao R; Burton JB; Brakenhielm E; Religa P; Galter D; Wu L; Cao Y
    Cancer Res; 2005 Oct; 65(20):9261-8. PubMed ID: 16230387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
    Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Merkel cell carcinoma induces lymphatic microvessel formation.
    Werchau S; Toberer F; Enk A; Dammann R; Helmbold P
    J Am Acad Dermatol; 2012 Aug; 67(2):215-25. PubMed ID: 22050913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis.
    Ochi N; Matsuo Y; Sawai H; Yasuda A; Takahashi H; Sato M; Funahashi H; Okada Y; Manabe T
    Pancreas; 2007 May; 34(4):444-51. PubMed ID: 17446844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm.
    Kim KE; Koh YJ; Jeon BH; Jang C; Han J; Kataru RP; Schwendener RA; Kim JM; Koh GY
    Am J Pathol; 2009 Oct; 175(4):1733-45. PubMed ID: 19762711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
    Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
    Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
    Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
    Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The VEGF-C/VEGFR3 signaling pathway contributes to resolving chronic skin inflammation by activating lymphatic vessel function.
    Hagura A; Asai J; Maruyama K; Takenaka H; Kinoshita S; Katoh N
    J Dermatol Sci; 2014 Feb; 73(2):135-41. PubMed ID: 24252749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins.
    Karkkainen MJ; Haiko P; Sainio K; Partanen J; Taipale J; Petrova TV; Jeltsch M; Jackson DG; Talikka M; Rauvala H; Betsholtz C; Alitalo K
    Nat Immunol; 2004 Jan; 5(1):74-80. PubMed ID: 14634646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
    Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis.
    Hos D; Regenfuss B; Bock F; Onderka J; Cursiefen C
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5778-85. PubMed ID: 21666240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of tumor cells and lymphatic vessels in cancer progression.
    Alitalo A; Detmar M
    Oncogene; 2012 Oct; 31(42):4499-508. PubMed ID: 22179834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
    Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
    Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
    J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.